Fig. 6From: Mechanisms of Cynarine for treatment of non-alcoholic fatty liver disease based on the integration of network pharmacology, molecular docking and cell experimentThe docking conformation between Cynarine and major therapeutic genes. A GSK3B, B MAPK1, and C AKT1Back to article page